gtcb really doesn't spend tons of money in biotech land. They did have a flawed business plan with their lead program as Atryn. Sales potential was too small to mean anything for investors. They had always thought get something approved and that's the proof of concept, partners will line up. Meanwhile they should have focused on something with more upside. Even if Atryn gets approved and I don't think it will on its first pass. Yawn. imo.
News 
Market Data 
Discover 
AI
